In 2023, the standardised mortality rate for prostate malignant neoplasms in Japan stood at 13.0 male deaths per hundred thousand men. The forecasted data for 2024 indicates a value of 12.9, representing a slight decrease. The trend continues with marginal declines, showing a projected decrease to 12.8 in 2025 and maintaining the same rate in 2026, before decreasing to 12.7 in 2027 and 12.6 in 2028. The year-on-year variations for these forecasted years display slight declines of approximately 0.8% annually, indicating a steady but slow reduction in mortality rates over time.
Future trends to watch for include advancements in early detection and treatment of prostate cancer, which could accelerate the declining mortality rates. Additionally, potential demographic shifts, such as the aging population in Japan, may affect these rates differently and highlight the need for sustained healthcare interventions.
- 2023: Base year at 13.0 deaths per hundred thousand men.
- 2024: Forecast at 12.9 with a decline from previous year.
- 2025-2028: Continued decrease in mortality rates.
- CAGR indicates a slow, steady decline over the forecasted period.
